HRP20020574B1 - Spojevi uree koji djeluju kao antagonisti muskarinskog receptora - Google Patents

Spojevi uree koji djeluju kao antagonisti muskarinskog receptora

Info

Publication number
HRP20020574B1
HRP20020574B1 HR20020574A HRP20020574A HRP20020574B1 HR P20020574 B1 HRP20020574 B1 HR P20020574B1 HR 20020574 A HR20020574 A HR 20020574A HR P20020574 A HRP20020574 A HR P20020574A HR P20020574 B1 HRP20020574 B1 HR P20020574B1
Authority
HR
Croatia
Prior art keywords
substituted
10alkyl
group
10aryl
element selected
Prior art date
Application number
HR20020574A
Other languages
English (en)
Inventor
Mammen Mathai
Oare David
Original Assignee
Theravance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance filed Critical Theravance
Publication of HRP20020574A2 publication Critical patent/HRP20020574A2/hr
Publication of HRP20020574B1 publication Critical patent/HRP20020574B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Spoj formule (Ia): naznačen time, da: A predstavlja fenil ili piridil; B'' predstavlja -NH-;R1 predstavlja vodik; R2 predstavlja pirolil, piridinil, imidazolil ili fenil; K predstavlja vezu ili metilensku skupinu; K'' predstavlja vezu; B predstavljapirolidin, piperidin ili heksahidroazepin; R46 predstavlja C1-10alkil, supstituirani C1-10alkil, C3-10cikloalkil, supstituirani C3-10cikloalkil ili C4-5heterociklički spoj R47 predstavlja C1-10alkil,supstituirani C1-10alkil, C6-10aril, acil, C4-5heterociklički spoj ili -COOR50 u kojem R50 predstavlja C1-10alkil; iliR46 i R47 zajedno s atomom dušika za kojeg su vezani predstavljaju C4-5heterociklički spoj, koji je opcionalno supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koja se sastoji od alkoksi, supstituiranog alkoksi, C3-10cikloalkila, supstituiranog C3-10cikloalkila, C4-8cikloalkenila, supstituiranog C4-8cikloalkenila, acila, acilamino, aciloksi, amino, supstituiranog amino, aminoacila, aminoaciloksi, oksiaminoacila, azido, cijano, halogena, hidroksila, keto, tioketo, karboksila, karboksilC1-10alkila, C6-10aril-S-, C4-8heteroaril-S-, C4-5heterociklik-S-tiola, C1-10alkil-S-, supstituiranog C1-10alkil-S-, C6-10arila, C6-10aril-O-, C4-8heteroarila, C4-8heteroaril-O-, C4-5heterociklika, C-4-8heterociklik-O-, hidroksiamino, alkoksiamino, nitro, -SO-C1-10alkila, supstituiranog -SO-C1-10alkila, -SO-C6-10arila, -SO-C4-8heteroarila, -SO2-C1-10alkila, supstituiranog -SO2-C1-10alkila, -SO2-C6-10arila, -SO2C1-10-heteroarila, C1-10alkila, supstituiranog C1-10alkila, C2-10alkenila, supstituiranog C2-10alkenila,C2-6alkinila i supstituiranog C2-6alkinila; X predstavlja skupinu formule: -Xa-Z- (Ya-Z)m-Yb-Z-Xa koja je naznačena slijedećim elementima m predstavlja cijeli broj od 0 do 20; Xa predstavlja u svakomzasebnom slučaju element odabran iz skupine koja se sastoji od -O-, -S-, -NR-, -C(O)-, -C(O)O-, -C(O)NR-, -C(S)-, -C(S)O-, -C(S)NR- ili kovalentne veze; Z u svakom pojedinom slučaju predstavlja element odabran iz skupine koja se sastoji od C1-3alkilena, supstituiranog C1-3alkilena, C3-10cikloalkilena, supstituiranog C3-10cikloalkilena, C2-3alkenilena, supstituiranog C2-3alkenilena, C2-3alkinilena, supstituiranog C2-3alkinilena, C4-8cikloalkenilena, supstituiranog C4-8cikloalkenilena, C6-10arilena, C5-10heteroarilena, C4-5heterociklena ili kovalentne veze; Ya i Yb u svakom pojedinom slučaju predstavljaju element odabran iz skupine koja se sastoji od -O-, -C(O)-, -OC(O)-, -C(O)O-, -NR, S(O)n-, -C(O)NR'-, -NR'C(O)-, -NR'C(O)NR'-, -NR'C(S)NR'-, -C(=NR')-NR'-, -NR'C(=NR')-, -OC(O)-NR'-, -NR'-C(O)-O-, -N=C(R'')-NR'-, -NR'-C(R'')=N-, -P(O)(OR')-O-, -O-P(O)(OR')-, -S(O)nCR'R''-, -S(O)n-NR'-, -NR'-S(O)n-, -S-S-, i kovalentne veze; gdje n predstavlja 0, 1 ili 2; i R, R' i R'' u svakom pojedinomslučaju predstavljaju element odabran iz skupine koja se sastoji od vodika, C1-10alkila, supstituiranog C1-10alkila, C3-10cikloalkila, supstituiranogC3-10cikloalkila, C2-10alkenila, supstituiranog C2-10alk
HR20020574A 1999-12-07 2002-07-04 Spojevi uree koji djeluju kao antagonisti muskarinskog receptora HRP20020574B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45617099A 1999-12-07 1999-12-07
PCT/US2000/033155 WO2001042213A1 (en) 1999-12-07 2000-12-07 Urea compounds having muscarinic receptor antagonist activity

Publications (2)

Publication Number Publication Date
HRP20020574A2 HRP20020574A2 (en) 2005-08-31
HRP20020574B1 true HRP20020574B1 (hr) 2007-12-31

Family

ID=23811737

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020574A HRP20020574B1 (hr) 1999-12-07 2002-07-04 Spojevi uree koji djeluju kao antagonisti muskarinskog receptora

Country Status (27)

Country Link
US (3) US6635764B2 (hr)
EP (2) EP1457488B1 (hr)
JP (1) JP2003516391A (hr)
KR (1) KR100748150B1 (hr)
CN (1) CN1271054C (hr)
AT (2) ATE271039T1 (hr)
AU (1) AU782232B2 (hr)
BR (1) BR0015963A (hr)
CA (1) CA2392030C (hr)
CZ (1) CZ20021830A3 (hr)
DE (2) DE60042762D1 (hr)
EA (1) EA006437B1 (hr)
ES (3) ES2243333T3 (hr)
HK (1) HK1049483B (hr)
HR (1) HRP20020574B1 (hr)
HU (1) HUP0203677A2 (hr)
IL (2) IL149289A0 (hr)
IS (1) IS2191B (hr)
MX (1) MXPA02005602A (hr)
NO (1) NO323544B1 (hr)
NZ (1) NZ518722A (hr)
PL (1) PL364922A1 (hr)
SK (1) SK7982002A3 (hr)
UA (1) UA73543C2 (hr)
WO (1) WO2001042213A1 (hr)
YU (1) YU42402A (hr)
ZA (2) ZA200204553B (hr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN100378092C (zh) * 2003-02-14 2008-04-02 施万制药 联苯衍生物
AU2004228028B2 (en) 2003-04-03 2009-12-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA009387B1 (ru) 2003-04-11 2007-12-28 Рэнбакси Лабораториз Лимитед Азабициклические производные в качестве антагонистов мускаринового рецептора
AU2004252102A1 (en) * 2003-06-23 2005-01-06 Gilead Palo Alto, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
US7368463B2 (en) * 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
UY28538A1 (es) * 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
EP1723113A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7262205B2 (en) 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528410A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
WO2005087734A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2005112988A2 (en) * 2004-05-21 2005-12-01 The Regents Of The University Of California Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1)
EP1778626A1 (en) * 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
US7880007B2 (en) 2004-11-29 2011-02-01 Vertex Pharmaceuticals Incorporated Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
GB0503054D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
EP1856049A1 (en) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7642355B2 (en) * 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1856112A1 (en) * 2005-03-10 2007-11-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
JP2008546695A (ja) * 2005-06-13 2008-12-25 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US7973055B2 (en) * 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
KR20090107567A (ko) * 2007-02-09 2009-10-13 아스텔라스세이야쿠 가부시키가이샤 아자 가교환 화합물
JP2011506477A (ja) * 2007-12-14 2011-03-03 セラヴァンス， インコーポレーテッド ムスカリン受容体拮抗薬として有用なアミジン含有化合物
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
TR201903556T4 (tr) 2009-04-23 2019-04-22 Theravance Respiratory Co Llc Muskarinik reseptör antagonisti ve beta 2 adrenerjik reseptör agonisti aktivitesine sahip diamid bileşikleri.
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
CN103168038A (zh) * 2010-10-20 2013-06-19 奇斯药制品公司 用于治疗咳嗽的碳酸酯衍生物
JP6021616B2 (ja) * 2012-12-04 2016-11-09 株式会社アエタスファルマ ３−ピペラジニル−１−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物
KR101514320B1 (ko) * 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물
SG10202000463YA (en) 2014-06-06 2020-02-27 Astellas Pharma Inc 2-acylaminothiazole derivative or salt thereof
US20210355114A1 (en) * 2018-10-24 2021-11-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2020204548A1 (ko) * 2019-03-29 2020-10-08 재단법인 의약바이오컨버젼스연구단 항암활성을 갖는 신규한 화합물 및 이의 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3402060A1 (de) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4675326A (en) 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
HUT72321A (en) * 1992-03-31 1996-04-29 Glaxo Group Ltd Substituted phenylcarbamate and phenyl-urea derivatives, pharmaceutical compositions containing them and process for their preparation
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (fr) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
WO1995021820A1 (fr) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US5691323A (en) 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
AU7145996A (en) * 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
EP0923374A1 (en) * 1996-07-01 1999-06-23 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s)-trihexyphenidyl
US6500934B1 (en) 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6062766A (en) * 1997-08-04 2000-05-16 Quixote Corporation Raised pavement marker
EP1047691A1 (en) * 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US6086881A (en) * 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US7238709B2 (en) * 1999-12-07 2007-07-03 Theravance, Inc. Therapeutic carbamates
WO2001098458A2 (en) * 2000-06-19 2001-12-27 Zyomyx, Inc. Methods for immobilizing polypeptides

Also Published As

Publication number Publication date
AU1951801A (en) 2001-06-18
EA006437B1 (ru) 2005-12-29
US20040054187A1 (en) 2004-03-18
EA200200646A1 (ru) 2002-12-26
IL149289A0 (en) 2002-11-10
UA73543C2 (uk) 2005-08-15
IS6362A (is) 2002-04-26
BR0015963A (pt) 2002-08-06
NZ518722A (en) 2004-03-26
WO2001042213A1 (en) 2001-06-14
ES2243333T3 (es) 2005-12-01
NO20022683L (no) 2002-07-02
DE60012223T2 (de) 2005-08-25
ES2329785T3 (es) 2009-12-01
CA2392030C (en) 2009-08-18
CZ20021830A3 (cs) 2002-10-16
CA2392030A1 (en) 2001-06-14
ATE271039T1 (de) 2004-07-15
PL364922A1 (en) 2004-12-27
HK1049483B (zh) 2005-02-18
IL149289A (en) 2007-05-15
EP1457488A1 (en) 2004-09-15
HRP20020574A2 (en) 2005-08-31
CN1271054C (zh) 2006-08-23
NO323544B1 (no) 2007-06-11
CN1407970A (zh) 2003-04-02
KR100748150B1 (ko) 2007-08-09
ES2225275T3 (es) 2005-03-16
HUP0203677A2 (hu) 2003-03-28
ZA200204557B (en) 2003-09-08
EP1457488B1 (en) 2009-08-12
KR20020058083A (ko) 2002-07-12
EP1235803A1 (en) 2002-09-04
US20020049195A1 (en) 2002-04-25
SK7982002A3 (en) 2002-12-03
IS2191B (is) 2007-01-15
US6635764B2 (en) 2003-10-21
AU782232B2 (en) 2005-07-14
ZA200204553B (en) 2003-09-08
HK1049483A1 (en) 2003-05-16
ATE439345T1 (de) 2009-08-15
JP2003516391A (ja) 2003-05-13
MXPA02005602A (es) 2004-09-10
EP1235803B1 (en) 2004-07-14
YU42402A (sh) 2006-01-16
DE60042762D1 (de) 2009-09-24
NO20022683D0 (no) 2002-06-06
US20040116706A1 (en) 2004-06-17
DE60012223D1 (de) 2004-08-19

Similar Documents

Publication Publication Date Title
HRP20020574B1 (hr) Spojevi uree koji djeluju kao antagonisti muskarinskog receptora
CA2238818A1 (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists
AU720923B2 (en) Dihydropyridine NPY antagonists: piperidine derivatives
RU2005114489A (ru) N-акрил-4-метиленамино-3-гидрокси-2-пиридоны в качестве противомикробных препаратов
HRP20090093T3 (hr) Supstituirani aril i heteroaril derivati kao modulatori metabolizma te profilaksa i liječenje pripadajućih poremećaja
ATE375331T1 (de) Amidderivate als inhibitoren der glycogensynthasekinase-3-beta
HUP0400326A2 (hu) Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
EE200100528A (et) Asendatud bitsükliline heteroarüülühend, seda sisaldav farmatseutiline kompositsioon ning nende raviotstarbeline kasutamine
AR028782A1 (es) Derivados heterociclicos tetrahidropiridino o piperidino
MX9803407A (es) Derivados de piperazina 1-(1,2-disustituido piperidinil)-4-sustituidos.
EA200601177A1 (ru) Пиридо- и пиримидопиримидиновые производные в качестве антипролиферативных агентов
CY1107221T1 (el) Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
NO331165B1 (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter
HUP0303070A2 (hu) 3,4-Dihidro-izokinolin-származékok és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
MX2009013335A (es) Derivados de piperidina/piperazina.
BG103983A (en) Gastrokinetic bicyclic benzamides of 3- or 4-substuituted 4-(aminomethyl)-piperidine derivatives
CA2238817A1 (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
NO20061126L (no) Aminopyroner og deres anvendelse som ATM-inhibitorer
RU2008147095A (ru) Макролидные производные
AR074862A1 (es) Derivados de heterociclo biciclicos y sus metodos de uso
DE69514341T2 (de) Amidino-derivative als no-synthese-inhibitoren
CY1106356T1 (el) Νεα υποκατεστημενα παραγωγα 4-φαινυλ-4-[1η-ιμιδαζολ-2-υλ]-πιπepιδινης και η χρηση τους ως επιλεκτικοι μη-πεπτιδικοι δελτα οπιοειδεις συναγωνιστες
IE901799L (en) Anti inflammatory aminophenol derivatives
NO20071112L (no) Nye heterosykliske karboksylsyreamidderivater

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: THERAVANCE BIOPHARMA R&D IP, LLC, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181121

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191122

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20201207